News Genmab A/S Nasdaq

Stocks

GMAB

US3723032062

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:01 27/06/2026 HKT			5-day change	1st Jan Change
26.12 ^USD	-0.08%		+3.36%	-15.19%

06-24	AlphaValue/Baader Europe Reduces EPS Estimates for Genmab on Merger Financing Costs	MT
06-23	Genmab: Financing weighs now, pipeline pays later

All News

Mentions Relevance

06-24	AlphaValue/Baader Europe Reduces EPS Estimates for Genmab on Merger Financing Costs	MT
06-23	Genmab: Financing weighs now, pipeline pays later
06-17	Genmab A/S : has published its Articles of Association	PU
06-17	Capital Increase in Genmab as a Result of Employee Warrant Exercise	GL
06-17	Capital Increase in Genmab as a Result of Employee Warrant Exercise	AQ
06-16	Major Shareholder Announcement	GL
06-16	Major Shareholder Announcement	AQ
06-15	Genmab A/S : has published its Articles of Association	PU
06-14	Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)	BU
06-14	Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)	GL
06-14	Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma	CI
06-12	Grant of Restricted Stock Units and Warrants to Employees in Genmab	GL
06-11	Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits	MT
06-11	Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients	BU
06-11	Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients	GL
06-11	Genmab A/S Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy And Safety Results For Epcoritamab In Combination With Rituximab And Lenalidomide R2 Across Relapsed Or Refractory Follicular Lymphoma Patients	CI
05-30	Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons	GL
05-22	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology Annual Meeting and the European Hematology Association 2026 Congress	AQ
05-22	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress	BU
05-22	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress	GL
05-18	Genmab Maintained at Buy as BofA Notes Upcoming Key Catalysts	MT
05-13	Genmab A/S : Articles of association dated May 12, 2026 – English	PU
05-13	Genmab A/S : has published its Articles of Association	PU
05-13	Capital Increase in Genmab as a Result of Employee Warrant Exercise	GL
05-12	Nordea resumes coverage of Genmab with Buy rating and DKK 2,015 price target	FW